<DOC>
	<DOCNO>NCT01077245</DOCNO>
	<brief_summary>Patients confirm C. difficile infection ( CDI ) meet eligibility requirement invited participate . All study patient must receive treatment CDI metronidazole vancomycin . Enrolled patient randomize 1:1 ratio receive MIYA-BM Fines Granules [ Clostridium butyricum MIYAIRI 588 Strain ( CBM588 ) ] placebo orally twice day 42 day . Patients evaluate safety clinical outcome Day 180 . Occurrence adverse event ( AEs ) , diarrhea history , concomitant medication evaluate schedule study visit telephone contact .</brief_summary>
	<brief_title>Safety Clinical Effectiveness Oral Probiotic MIYA-BM Prevent Recurrent Clostridium Difficile Infections</brief_title>
	<detailed_description>This study Phase 2 blind , placebo-controlled , randomized clinical trial oral probiotic product , MIYA-BM Fine Granules [ Clostridium butyricum MIYAIRI 588 Strain ( CBM588 ) ] , patient diagnose CDI treat metronidazole vancomycin . Two hundred patient meet eligibility criterion randomize 1:1 fashion receive either MIYA-BM ( 2g/dose ) placebo orally twice daily 42 day . After randomization , patient follow total 180 day ( 6 month ) safety recurrent CDI . If initially hospitalize , patient follow daily diarrhea history , collection concomitant medication AEs , monitor response treatment . Patients follow clinic visit safety telephone call . All patient give Diary Card report AEs , diarrhea history , concomitant medication daily basis . If patient sign symptom CDI follow resolution initial episode , instructed return clinic soon possible evaluation recurrent CDI . If patient diagnose recurrent CDI , discontinue study treatment ( MIYA-BM placebo ) treat follow accord institution 's standard care recurrent CDI .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>Adult either gender , age 1880 year old inclusive Meets case definition CDI recent history diarrhea presence C. difficile toxin pseudomembranous colitis ; know etiology diarrhea ( e.g . enteric pathogen , intestinal disease ) CDI treat metronidazole vancomycin If female reproductive potential , subject must pregnant ( negative pregnancy test time screen ) breastfeeding , currently use reliable method birth control Has know etiology diarrhea ( e.g . enteric pathogen , intestinal disease ) Has history acute pancreatitis within last 3 month Has history chronic intestinal disease ( e.g . Crohn 's disease , ulcerative colitis ) Is unable complete daily study diary ( mental incapacity , head trauma , etc . ) Has presence toxic megacolon ileus Has presence colostomy , nasogastric tube , indwell central line Has history abdominal surgery within previous 3 month ( time enrollment ) Has recent history investigational drug use within 30 day enrollment visit Has plan investigational drug use participate study Is know HIV infection AIDS immunosuppressive disease Has take systemic immunosuppressive drug within 60 day enrollment Is currently take plan use oral probiotic , yogurt , study Has know allergy component MIYABM Fine Granules placebo Is unavailable followup visit At enrollment , social medical condition , psychiatric illness , opinion investigator , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>Clostridium Infections</keyword>
	<keyword>Gram-Positive Bacterial Infections</keyword>
	<keyword>Bacterial Infections</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Clostridium butyricum</keyword>
	<keyword>Metronidazole</keyword>
	<keyword>Vancomycin</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Enterocolitis , Pseudomembranous</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Enterocolitis</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Colitis</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Probiotics</keyword>
	<keyword>Gastrointestinal Agents</keyword>
</DOC>